Related Experiment Video

Updated: Feb 10, 2026

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
11:27

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging

Published on: December 4, 2016

10.6K

Comparison of Two Neutral Oral Contrast Agents in Pediatric Patients: A Prospective Randomized Study

Jonathan R Dillman1, Alexander J Towbin1, Rebecca Imbus1

  • 1From the Department of Radiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, ML 5031, Cincinnati, OH 45229.

Radiology
|May 9, 2018
PubMed

Insights

Breeza and barium sulfate suspension offer similar small bowel distention for pediatric enterography. Patients preferred Breeza due to better taste and texture, leading to higher completion rates.

Area of Science:

  • Radiology
  • Pediatric Imaging
  • Gastroenterology

Background:

  • Oral contrast agents are crucial for cross-sectional enterography.
  • Optimizing patient acceptance and adherence is vital for successful pediatric imaging.
  • Neutral contrast agents are preferred for computed tomographic (CT) and magnetic resonance (MR) enterography.

Purpose of the Study:

  • To prospectively compare small bowel distention and patient acceptance of two neutral oral contrast materials in pediatric patients.
  • To evaluate Breeza against a low-density barium sulfate suspension for cross-sectional enterography.
  • To determine if Breeza offers superior taste and texture compared to barium sulfate suspension.

Main Methods:

  • A noninferiority study randomized 66 pediatric patients to receive either Breeza or barium sulfate suspension.
  • Patients rated taste, texture, and perceived health state; ingested volume was recorded.
  • Maximum small bowel diameter was measured, and data were analyzed using t tests and Fisher exact tests.

Main Results:

  • Both Breeza and barium sulfate suspension provided similar small bowel distention (mean diameter 1.63 cm vs 1.69 cm, P = .44).
  • Significantly more patients completed the Breeza preparation (84.8%) compared to barium sulfate suspension (51.5%, P = .007).
  • Breeza received higher scores for taste (P < .0001) and texture (P < .0001).

Conclusions:

  • Breeza and low-density barium sulfate suspension are comparable in achieving adequate small bowel distention for pediatric enterography.
  • Breeza demonstrates superior patient acceptance, evidenced by better taste and texture ratings.
  • Improved patient acceptance of Breeza leads to higher adherence and completion rates, enhancing imaging quality.

More Related Videos

Whole-body PET/MRI of Pediatric Patients: The Details That Matter10:02

Whole-body PET/MRI of Pediatric Patients: The Details That Matter

Published on: December 19, 2017

15.4K
Guidelines for Elective Pediatric Fiberoptic Intubation11:19

Guidelines for Elective Pediatric Fiberoptic Intubation

Published on: January 17, 2011

18.6K

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
687
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.2K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
274
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
330
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
245
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
687